Attendee search 

WEGO HOLDING COMPANY LIMITED (“WEGO”) was established in March 1988, and it principal business focus on medical devices and pharmaceuticals. In addition, WEGO develops some other business such as real estate and investment. WEGO has 8 industry groups and more than 30 subsidiaries. WEGO Holding's subsidiary ---SHANDONG WEIGAO GROUP MEDICAL POLYMER CO., LIMITED is listed in Hong Kong.

The main products of WEGO are infusion sets, syringes, blood transfusion equipments, heart stents, intracardiac consumables，IV catheters and special needles, blood purification equipments and consumables, orthopedic materials, operating room equipments and accessories, wound care products, minimally invasive instruments and equipments, ICU products and accessories, high-capacity injections and pharmaceuticals, renal products, biological diagnostic reagents, PVC & non-PVC materials and so on. WEGO now has products in more than 30 series, 400 categories and 60,000 specifications products, and has become one of the most reliable suppliers of medical system solutions in the world. At the same time, WEGO actively takes part in healthcare service and provides renal dialysis service.

In addition, under the branding strategy, the WEGO products are sold in more than 30 provinces and municipalities, which covered 81.3% of tertiary hospitals and 77.2% of blood banks in China, and also exported to over 70 countries and areas. WEGO is trying to become an international company, trying to achieve the vision of “To be one of the global elites; Pioneer in Asia; Most respectable medical device and medication enterprise”, and trying to make contributions to China's medical and healthcare industry.

OneWorld Diagnostics is a German biotech company which focuses on veterinary diagnostics solutions and R&D tools and products. With our professional services and customized research solution, OneWorld Diagnostics is a trusted contract research organization specializing in diagnostic assay development and tech transfer. We are the trusted partner of the Top 5 international and Chinese pharmaceutical companies.
Our expertise is in developing research solution particularly in microbiology, molecular and immunology assay development and tech transfer in China and European markets.

Replace eye drops from FREEDOM drug releasing clear contact lens corneal bandage. The device has a 7 day wear time consistent with the standard of care recall after; cataract, LASIK surgery & corneal abrasion & non infectious Uveitis. Doctor puts device on and takes it off eliminating patient compliance problems with quicker healing with drug constantly treating the target tissue. 10 granted patents with FTO legal opinion. 10 mono and combo ophthalmic Dougs tested. Completed in vivo safety study. Letter and meeting being set with the US FDA for phase 1-2 clinical in January 2021.

Venture Capital and fundraising for fast growing companies. Action means action.

Venn Biosciences innovates cancer diagnostics using Artificial Intelligence (AI) and next-gen mass spectrometry, unlocking glycoproteomics for Biomarker and Target Discovery.

Life science-focused Innovation licensing organizations looking to commercialize global innovations for the Indian and South Asian markets through a unique partnership-led model.

Libera Bio develops a new family of cancer treatments based on its patented actively targeted delivery technology to intracellular targets (MPN – Multifunctional Polymeric Nanocapsules) and on novel monoclonal antibodies (e.g. anti KRAS), with the goal to have them commercialized by large biopharma companies after regulatory approval for clinical trials or early proof-of-concept in humans.

Libera Bio lead candidate aims at providing a new treatment for those highly prevalent and aggressive cancers which are driven by KRAS mutations, such as pancreatic cancer, lung cancer and colorectal cancer.

跨国Medtech集团

Mend Biotech’s full name is Mend Biotechnology Incorporation, and its English name is Mend Biotech Inc. ( MBT). It is a multinational research institution focusing on the field of regenerative medicine to treat various skeletal-related diseases. The founding team consists of Professors and Scientists in Cedars-Sinai Medical center, UCLA and Harvard University and the kick school of medicine in USC, and the CEO of a multinational biotechnology company. In June 2020, MBT settled in CHENGDU TianFu international Bio-town as a key project introduced by Chengdu High-tech zone government. MBT received 13.5 million Chinese yuan in seed round investment by Mr. chen keming, chairman of keming noodle industry, a listed company in China. A follow on angel round is expected to generate an investment of 40 million. GMP and cGMP lab are currently under construction in both China and US.

Allakos is a public-traded clinical-stage biopharmaceutical company developing first-in-class antibody-based therapeutics to treat allergic and inflammatory diseases.